All In Biotech

Drug Trial Radar · NCT07812597

A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)

A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ)

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Jan 13, 2028

Study completion Mar 24, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity.

Conditions

  • Obesity

Interventions

  • zovaglutide Arm 1Drug

    Zovaglutide will be administered via subcutaneous (SC) injection.

  • zovaglutide Arm 2Drug

    Zovaglutide will be administered via subcutaneous (SC) injection.

  • semaglutideDrug

    Semaglutide will be administered via subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving successful switch from semaglutide 2.4 mg to zovaglutide after randomizationTime frame: from week 20 (randomization) to week 36

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, China

  • Handan First Hospital

    Handan, Hebei, China

  • Hebei Petro China Cental Hospital

    Langfang, Hebei, China

  • Harbin Medical University Affiliated Fourth Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated of Nanyang Medical College

    Nanyang, Henan, China

  • Yichang Central People's Hospital (Xiling Campus)

    Yichang, Hubei, China

  • The First People's Hospital of Changde

    Changde, Hunan, China

  • Jilin Province FAW General Hospital

    Changchun, Jilin, China

  • The Fifth People's Hospital of Shenyang

    Shenyang, Liaoning, China

  • Central Hospital Affiliated to Shandong First Medical University

    Jinan, Shandong, China

  • Zibo Central Hospital

    Zibo, Shandong, China

  • Zibo Municipal Hospital

    Zibo, Shandong, China

  • Jincheng General Hospital

    Jincheng, Shanxi, China

  • The 2nd People's Hospital of Chengdu

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.